Silence Therapeutics Reports Q2 2025 Progress and Financials

Silence Therapeutics Plc ( (SLN) ) has released its Q2 earnings. Here is a breakdown of the information Silence Therapeutics Plc presented to its investors.

Silence Therapeutics is a global clinical-stage biotechnology company focused on developing innovative siRNA therapies to target and silence disease-associated genes, particularly in the liver, with a focus on areas of high unmet medical need such as cardiovascular disease, hematology, and rare diseases.

In its second quarter of 2025, Silence Therapeutics reported significant progress in its clinical trials and financial performance. The company highlighted updated data from the SANRECO Phase 1 study, showcasing the potential of its siRNA therapy, divesiran, for treating Polycythemia Vera (PV). Additionally, the company is on track to complete enrollment for the SANRECO Phase 2 study by the end of the year.

Financially, Silence Therapeutics ended the quarter with $114.2 million in cash and short-term investments, providing a cash runway into 2028. The company reported an increase in research and development expenses to $17.6 million, primarily due to the advancement of clinical trials and manufacturing activities. General and administrative expenses decreased to $5.1 million, reflecting improved operational efficiencies. However, the net loss for the quarter widened to $27.4 million compared to the previous year.

Strategically, Silence Therapeutics is advancing its siRNA programs, including zerlasiran for cardiovascular disease, and is in discussions with potential partners for Phase 3 development. The company is also prioritizing extra-hepatic cell targeting of siRNA, pausing other projects to focus on promising preclinical activities.

Looking ahead, Silence Therapeutics remains committed to advancing its clinical programs and collaborations, with a focus on delivering near-term value and maintaining a strong financial position to support its long-term strategic goals.